top of page
  • Active, not recruiting

NCT01754402: Phase 1 / 2 - Bendamustine + Pomalidomide + Dex in Relapsed Multiple Myeloma

Updated: Sep 27, 2022

This study is designed as a phase I-II, open label, dose finding study. Study treatment will be as follows, in 28 day cycles: Pomalidomide: once daily orally (PO) dosing on days 1-21, every 28 days I Bendamustine: once intravenously (IV) dosing on day 1, every 28 days I Dexamethasone: weekly PO or IV dosing on days 1, 8, 15, and 22. After completing 6 cycles of treatment, dexamethasone may be decreased to 20mg per investigator discretion. After completing 12 cycles of treatment, patients will proceed to the maintenance phase of the study. Patients will receive Pomalidomide on day 1-21, every 28 days and dexamethasone on days 1, 8, 15, and 22 every 28 days until time of progression.


Cristina Gasparetto


Celgene Identifier: NCT01754402

Official Title: A Phase I-II Study of the Combination of Bendamustine and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

First Posted : December 21, 2012


Pomalidomide: National Cancer Institute

Pomalidomide: MedlinePlus Drug Information

Bendamustine: National Cancer Institute

Bendamustine: MedlinePlus Drug Information

Dexamethasone : National Cancer Institute

Dexamethasone : MedlinePlus Drug Information

Posts Archive
bottom of page